German Court Holds Firms Liable for AI Errors, as Healthcare System Faces New Strain
14.06.2026 - 16:22:22 | boerse-global.de
A recent ruling by the Landgericht MĂĽnchen has put tech companies on notice: AI-generated summaries in search results are no longer protected as mere previews. The court found that an operator who published faulty content created by an artificial intelligence system could be held fully responsible for any inaccuracies. According to the judges, such texts count as independent content, not just link previews, meaning the provider bears legal liability for the information they contain.
The decision came as part of proceedings over incorrect AI summarisations in search results, and it sets a clear precedent for digital platforms operating in Germany. It echoes the broader regulatory shift underway: on 12 June, the Bundestag passed the national implementing law for the EU’s AI regulation. Under the new rules, the Bundesnetzagentur will become the country’s central market-surveillance authority for artificial intelligence. The agency will handle complaints and run “reallabore” — experimental spaces for AI development. Companies that violate the rules could face fines of up to 50,000 euros.
Parallel to that legislative push, the healthcare system is wrestling with its own set of challenges. Since 13 June, patients with mild respiratory illnesses or COVID-19 symptoms can once again obtain a sick note over the phone — a practice the Gemeinsamer Bundesausschuss reinstated until 30 November. Doctors are allowed to certify incapacity for work for up to one week by telephone, and can extend it once for another seven days. The aim is to ease the burden on surgeries and prevent infection chains in waiting rooms.
Meanwhile, Health Minister Warken presented the new Beitragssatzstabilisierungsgesetz before the Bundestag on 12 June. The bill addresses a projected financing gap of 2.5 billion euros for 2027 and additional costs of 3.5 billion euros for 2026. It is scheduled for adoption before the summer break by 10 July. The proposed cuts met fierce opposition. Pharmaceutical industry representatives criticised the expected financial burden. Eli Lilly and Boehringer Ingelheim have already announced they will either heavily scale back planned investments at German sites or cancel them entirely.
The Minister defended the move, stating that every sector must contribute to the system’s stability. But criticism is mounting also from medical associations. Participants at the 5th German Psychotherapy Congress in Berlin warned in June of a looming crisis in outpatient care due to threatened fee reductions and budget caps. Rhineland-Palatinate’s Minister-President Gordon Schnieder went a step further, demanding changes on 12 June — particularly regarding rebates for patent-protected medicines.
On the legal front, the Bundesgerichtshof clarified earlier precedents that shape how patient data can be shared. Hospitals must, under certain conditions, disclose the address of a fellow patient — for example, when someone seeks damages for an alleged assault by that other patient. In such cases, the interest in legal enforcement outweighs medical confidentiality and data protection. However, the Amtsgericht Köln ruled that an attorney’s duty of confidentiality can block a data access claim if the information was obtained during a client mandate relationship, allowing patient data to stay protected when legal professional privilege applies.
